



PATENT  
Atty Dkt: 203442102500

hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Assistant Commissioner for Patents, Washington,  
D.C. 20231 on SEPT. 14, 1995

9/14/95  
Date

Jan Gumprie  
Signature

AJ  
P#6  
10/30/95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

VISHVA M. DIXIT

Serial No.: 08/404,832

Group Art Unit: 1814

Filing Date: March 13, 1995

Examiner: Unassigned

Title: CD40 BINDING COMPOSITIONS  
AND METHODS OF USING SAME

SUPPLEMENTAL INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner  
for Patents  
Washington, D.C. 20231

RECEIVED  
OCT 18 1995  
GROUP 1800

Dear Sir:

The information listed below was cited in an International (PCT) Search Report completed August 2, 1995, directed to the corresponding PCT Application Serial Number PCT/US95/06623. A copy of the Search Report, including an indication of the purported relevance of the cited documents, is submitted herewith. Copies of the references are also enclosed. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

Cheng et al., "Involvement of CRAF1, a relative of TRAF, in CD40 signaling" Science (1995) 267:1494-1498.

PATENT  
USSN 08/404,832  
Atty Dkt 203442102500

Sato et al., "A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40" FEBS Letters (1995) 358:113-118.

Mosialos et al., "The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family" Cell (1995) 80:389-399.

Irie et al., "A novel cDNA encoding a protein that binds the cytoplasmic domain of CD40" J. Cell. Biochem. (1995) Abstract Supplement 19A:36 (abstract no. A1-234).

The Examiner is requested to note that the first reference listed on the enclosed Search Report, namely Hu et al., J. Biol. Chem. (1994) 269:30069-30072, was previously disclosed in an Information Disclosure Statement dated July 7, 1995, directed to the above-identified application. Therefore, this reference is already of record in the instant application and a copy is not enclosed herewith.


This Supplemental Information Disclosure Statement is submitted before receipt of the first Office Action on Merits. Accordingly, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper to Deposit Account Number 03-1952.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

PATENT  
USSN 08/404,832  
Atty Dkt 203442102500

This Supplemental Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

By   
Antoinette F. Konski  
Registration No. 34,202

Date: Sept. 13, 1995

MORRISON & FOERSTER  
755 Page Mill Road  
Palo Alto, CA 94304-1018  
(415) 813-5600  
Fax: (415) 494-0792